Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
Recruiting · NCT05534646 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-10-05 | NCT05534646 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Edwin Posadas, MD | 2 |
| Kairos Pharma | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |
| City of Hope | Duarte | United States | 238 |
| Huntsman Cancer Institute and Hospital | Salt Lake City | United States | 1 |